Article Correctness Is Author's Responsibility: NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases

The article below may contain offensive and/or incorrect content.

The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program, aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.